November 202621

Once-daily 5% minoxidil foam in postmenopausal women was found to regrow hair regardless of severity, while follicular SULT1A1 testing was reported to predict topical minoxidil response. Cardiovascular events with oral minoxidil were found uncommon with no consistent excess risk, though risk exceeded topical minoxidil and women appeared more susceptible. Current androgenetic alopecia drugs were concluded to work best early and mainly preserve hair, with transplantation the only fix for lost follicles. Red-light and cold-conditioned PRP proved no better than conventional PRP. Hypertrichosis from low-dose oral minoxidil was associated with increased scalp hair density. Topical cetirizine showed no consistent advantage over minoxidil or as an add-on.

  1. Topical Minoxidil for Female Pattern Hair Loss: Clinical Outcomes in Postmenopausal Women A review with phase III post hoc data found once-daily 5% minoxidil foam regrew hair in postmenopausal women regardless of FPHL severity. Minoxidil Dermatologic Surgery
  2. Cardiovascular Safety of Oral Minoxidil Use in Hair-Loss Patients: A Systematic Review and Meta-Analysis A meta-analysis of 63 studies found cardiovascular events with oral minoxidil uncommon and no consistent excess risk versus comparators, though risk exceeded topical minoxidil and women appeared more susceptible; individualized monitoring research is still needed. Minoxidil British Journal of Dermatology
  3. Evaluating current and emerging pharmacological treatment options for men with androgenetic alopecia A review concludes current drugs work best early and mainly preserve hair; transplantation remains the only fix where follicles are lost. Androgenetic AlopeciaHair Transplant Expert Review of Clinical Pharmacology
  4. Personalized minoxidil therapy in androgenetic alopecia: from SULT1A1 biomarkers to precision clinical management A review explains how follicular SULT1A1 testing can predict topical minoxidil response and enable personalized treatment algorithms. Androgenetic AlopeciaMinoxidil Drug Metabolism Reviews
  5. Photo‐ and Temperature‐Conditioned Versus Conventional Platelet‐Rich Plasma for Androgenetic Alopecia: A Split‐Scalp, Double‐Blind, and Randomized Active‐Comparator Trial A split-scalp RCT in 21 AGA patients found red-light/cold-conditioned PRP no better than conventional PRP; both modestly increased hair shaft diameter. Androgenetic AlopeciaMinoxidilPlatelet-Rich Plasma Photodermatology Photoimmunology & Photomedicine
  6. Hypertrichosis with Low-Dose Oral Minoxidil is Associated with Increased Scalp Hair Density Hypertrichosis from low-dose oral minoxidil was associated with increased scalp hair density. Minoxidil Journal of the American Academy of Dermatology
  7. The Efficacy of Topical Cetirizine for Patients with Androgenetic Alopecia: A Systematic Review and Meta-analysis A meta-analysis found topical cetirizine showed no consistent advantage over minoxidil or as an add-on; evidence remains low-certainty and it is unproven. CetirizineMinoxidil Clinics in Dermatology
  8. Carnosic acid–loaded nanostructured lipid carriers for targeted follicular delivery and hair regeneration in androgenetic alopecia A carnosic acid nanocarrier gel regrew hair faster than 2% minoxidil and cut inflammatory markers more in a testosterone-induced alopecia model. Androgenetic AlopeciaMinoxidil Inflammopharmacology
  9. Curcumin-Loaded Zinc-Ginsenoside MOF Microneedles Attenuate Androgen-Induced Follicular Damage and Promote Hair Regrowth Curcumin-loaded ginsenoside-zinc microneedles blocked DHT damage and accelerated hair regrowth via Wnt/β-catenin in a mouse AGA model. Androgenetic AlopeciaZinc ACS Biomaterials Science & Engineering
  10. Forty-Eight-Week Real-World Outcomes of Ritlecitinib in Alopecia Areata: Delayed Responses and Predictive Value of Change in SALT Score at Week 24 Real-world ritlecitinib gave SALT ≤20 in 39% of severe AA patients by week 48, with some responding only after week 24. Alopecia AreataRitlecitinib Dermatology and Therapy
  11. Follicle-Targeted Deep Eutectic Solvent-Lipid Hybrid Nanocarriers for Phloretin against Androgenetic Alopecia A phloretin hybrid nanocarrier stimulated dermal papilla cells, cut inflammation, and regrew hair in AGA models via Wnt/β-catenin and mTOR. Androgenetic AlopeciaMinoxidil ACS Applied Materials & Interfaces
  12. Topical drug delivery for androgenetic alopecia: from hair follicle targeting to clinical translation A review surveys nanocarriers, microneedles and other follicle-targeted topical delivery systems for AGA and their translational challenges. Androgenetic Alopecia Journal of Controlled Release
  13. Janus Kinase Inhibitors for Severe Alopecia Areata: A Systematic Literature Review and Network Meta-Analysis A network meta-analysis estimated upadacitinib 30mg gave the highest week-24 SALT ≤20 rate (54%) among JAK inhibitors for severe AA. Alopecia AreataBaricitinibDeuruxolitinibRitlecitinibUpadacitinib Journal of Investigative Dermatology
  14. Intradermal Injection of Exocean Plant Derived Exosomes: Human Scalp Histological and Morphometric Changes Plant-exosome scalp injections in 30 adults increased follicular density and Ki67 on biopsy, but the uncontrolled multi-ingredient design prevents attribution. Exosomes Plastic & Reconstructive Surgery Global Open
  15. Treatment Timing and Early Hair Regrowth in Relation to Response to Intravenous Methylprednisolone Pulse Therapy in Alopecia Areata: A Retrospective Cohort Study In 72 alopecia areata patients, starting IV methylprednisolone within 6 months and 3-month regrowth predicted 6-month response. Alopecia Areata The Journal of Dermatology
  16. Alopecia areata-associated white hair growth can occur independent of follicular cycling White hair occurred in 16% of 5,155 AA patients, linked to age, autoimmunity and allergy; most regained pigment with treatment. Alopecia AreataAlopecia Totalis British Journal of Dermatology · 1 citation
  17. Color Doppler Ultrasound in Hair Transplant Planning for Cicatricial Alopecia In 22 cicatricial alopecia patients, ultrasound identified thin recipient sites needing fat grafting; graft survival exceeded 90% in 8 of 11 transplanted. Hair TransplantScarring Alopecia Journal of Ultrasound in Medicine
  18. Dupilumab and alopecia areata: direct effect, indirect effect, or endotype-specific response? A review questions whether dupilumab affects alopecia areata directly, indirectly, or by endotype. Alopecia Areata Expert Review of Clinical Pharmacology
  19. ROS‐Responsive Hydrogel Delivery of miR‐665 for Alopecia Areata: Mechanistic Insights and Translational Perspectives A commentary weighs the promise and unresolved translational barriers of a ROS-responsive hydrogel delivering miR-665 for alopecia areata. Alopecia Areata Advanced Biology
  20. MCP ‐1 From Aging Dermal Adipose Tissue Impairs Hair Follicle Cycling via Macrophage Recruitment: Implications for Age‐Related Alopecia In aged mice, MCP-1 from dermal fat recruited macrophages that stalled hair cycling; depleting macrophages restarted anagen and melanogenesis. Follistatin Aging Cell
  21. Comprehensive Hair Loss Treatment: Bridging Drugs and Medical Devices A review proposes combining drugs, devices and lifestyle measures into comprehensive hair-loss care without reporting new results. Androgenetic AlopeciaFinasterideHair TransplantMicroneedlingMinoxidil Clinical Cosmetic and Investigational Dermatology